-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, PainReform Ltd gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| CurrencyCode | USD |
| ISIN | IL0011651580 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| PE Ratio | None |
|---|---|
| Target Price | 12 |
| Market Cap | 4M |
| Beta | 0.72 |
| Dividend Yield | None |
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. the company develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PRFX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
